Advertisement

Estrogen Receptor β and Breast Cancer

  • Christoforos Thomas
  • Jan-Åke Gustafsson
Chapter
Part of the Cancer Drug Discovery and Development book series (CDD&D)

Abstract

Despite the primary role of estrogen receptor α (ERα) in mediating the effects of estrogen in malignant breast and as therapeutic target, the development of endocrine-resistant and metastatic phenotypes indicates the complexity of the mechanisms that regulate hormone signaling in the disease. The discovery of ERβ and its functional characterization has improved our understanding about the mechanism of estrogen receptor action, the regulation of estrogen signaling in breast tumors, and their response to therapy. The progressive decline of ERβ in pro-invasive lesions and invasive tumors points toward a role as suppressor of both tumorigenesis and progression in breast cancer. The antiproliferative and anti-invasive effects of the receptor and its agonists in preclinical models of breast cancer support these roles and delineate the mechanisms of action. The association of ERβ with clinical outcome proposes the potential use of the receptor as prognostic marker and its agonists in chemoprevention and therapeutic strategies for resistant and metastatic disease.

Keywords

Estrogen receptor β Breast cancer Estrogen signaling Breast cancer metastasis Breast cancer prognosis 

References

  1. 1.
    Thomas C, Gustafsson JA (2011) The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer 11(8):597–608.  https://doi.org/10.1038/nrc3093CrossRefPubMedGoogle Scholar
  2. 2.
    Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M, Gustafsson JA (2001) Mechanisms of estrogen action. Physiol Rev 81(4):1535–1565.  https://doi.org/10.1152/physrev.2001.81.4.1535CrossRefGoogle Scholar
  3. 3.
    Chang EC, Frasor J, Komm B, Katzenellenbogen BS (2006) Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology 147(10):4831–4842.  https://doi.org/10.1210/en.2006-0563CrossRefPubMedGoogle Scholar
  4. 4.
    Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17(5):1474–1481.  https://doi.org/10.1200/JCO.1999.17.5.1474CrossRefGoogle Scholar
  5. 5.
    Nelson AW, Groen AJ, Miller JL, Warren AY, Holmes KA, Tarulli GA, Tilley WD, Katzenellenbogen BS, Hawse JR, Gnanapragasam VJ, Carroll JS (2017) Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity. Mol Cell Endocrinol 440:138–150.  https://doi.org/10.1016/j.mce.2016.11.016CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Leygue E, Murphy LC (2013) A bi-faceted role of estrogen receptor beta in breast cancer. Endocr Relat Cancer 20(3):R127–R139.  https://doi.org/10.1530/ERC-12-0389CrossRefPubMedGoogle Scholar
  7. 7.
    Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y, Muramatsu M (1998) Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor of estrogen action in human. Nucleic Acids Res 26(15):3505–3512CrossRefGoogle Scholar
  8. 8.
    Katzenellenbogen JA, Katzenellenbogen BS (1996) Nuclear hormone receptors: ligand-activated regulators of transcription and diverse cell responses. Chem Biol 3(7):529–536CrossRefGoogle Scholar
  9. 9.
    Green S, Walter P, Greene G, Krust A, Goffin C, Jensen E, Scrace G, Waterfield M, Chambon P (1986) Cloning of the human oestrogen receptor cDNA. J Steroid Biochem 24(1):77–83CrossRefGoogle Scholar
  10. 10.
    Thomas C, Gustafsson JA (2015) Estrogen receptor mutations and functional consequences for breast cancer. Trends Endocrinol Metab 26(9):467–476.  https://doi.org/10.1016/j.tem.2015.06.007CrossRefPubMedGoogle Scholar
  11. 11.
    Leung YK, Gao Y, Lau KM, Zhang X, Ho SM (2006) ICI 182,780-regulated gene expression in DU145 prostate cancer cells is mediated by estrogen receptor-beta/NFkappaB crosstalk. Neoplasia 8(4):242–249.  https://doi.org/10.1593/neo.05853CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Leung YK, Mak P, Hassan S, Ho SM (2006) Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. Proc Natl Acad Sci U S A 103(35):13162–13167.  https://doi.org/10.1073/pnas.0605676103CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Souza PCT, Textor LC, Melo DC, Nascimento AS, Skaf MS, Polikarpov I (2017) An alternative conformation of ERbeta bound to estradiol reveals H12 in a stable antagonist position. Sci Rep 7(1):3509.  https://doi.org/10.1038/s41598-017-03774-xCrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Grober OM, Mutarelli M, Giurato G, Ravo M, Cicatiello L, De Filippo MR, Ferraro L, Nassa G, Papa MF, Paris O, Tarallo R, Luo S, Schroth GP, Benes V, Weisz A (2011) Global analysis of estrogen receptor beta binding to breast cancer cell genome reveals an extensive interplay with estrogen receptor alpha for target gene regulation. BMC Genomics 12:36.  https://doi.org/10.1186/1471-2164-12-36CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Zhao C, Gao H, Liu Y, Papoutsi Z, Jaffrey S, Gustafsson JA, Dahlman-Wright K (2010) Genome-wide mapping of estrogen receptor-beta-binding regions reveals extensive cross-talk with transcription factor activator protein-1. Cancer Res 70(12):5174–5183.  https://doi.org/10.1158/0008-5472.CAN-09-4407CrossRefPubMedGoogle Scholar
  16. 16.
    Charn TH, Liu ET, Chang EC, Lee YK, Katzenellenbogen JA, Katzenellenbogen BS (2010) Genome-wide dynamics of chromatin binding of estrogen receptors alpha and beta: mutual restriction and competitive site selection. Mol Endocrinol 24(1):47–59.  https://doi.org/10.1210/me.2009-0252CrossRefPubMedGoogle Scholar
  17. 17.
    Le TP, Sun M, Luo X, Kraus WL, Greene GL (2013) Mapping ERbeta genomic binding sites reveals unique genomic features and identifies EBF1 as an ERbeta interactor. PLoS One 8(8):e71355.  https://doi.org/10.1371/journal.pone.0071355CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Williams C, Edvardsson K, Lewandowski SA, Strom A, Gustafsson JA (2008) A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells. Oncogene 27(7):1019–1032.  https://doi.org/10.1038/sj.onc.1210712CrossRefPubMedGoogle Scholar
  19. 19.
    Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, Al-Zeer MA, Albert ML, Albin RL, Alegre-Abarrategui J, Aleo MF, Alirezaei M, Almasan A, Almonte-Becerril M, Amano A, Amaravadi R, Amarnath S, Amer AO, Andrieu-Abadie N, Anantharam V, Ann DK, Anoopkumar-Dukie S, Aoki H, Apostolova N, Arancia G, Aris JP, Asanuma K, Asare NY, Ashida H, Askanas V, Askew DS, Auberger P, Baba M, Backues SK, Baehrecke EH, Bahr BA, Bai XY, Bailly Y, Baiocchi R, Baldini G, Balduini W, Ballabio A, Bamber BA, Bampton ET, Banhegyi G, Bartholomew CR, Bassham DC, Bast RC Jr, Batoko H, Bay BH, Beau I, Bechet DM, Begley TJ, Behl C, Behrends C, Bekri S, Bellaire B, Bendall LJ, Benetti L, Berliocchi L, Bernardi H, Bernassola F, Besteiro S, Bhatia-Kissova I, Bi X, Biard-Piechaczyk M, Blum JS, Boise LH, Bonaldo P, Boone DL, Bornhauser BC, Bortoluci KR, Bossis I, Bost F, Bourquin JP, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady NR, Brancolini C, Brech A, Brenman JE, Brennand A, Bresnick EH, Brest P, Bridges D, Bristol ML, Brookes PS, Brown EJ, Brumell JH, Brunetti-Pierri N, Brunk UT, Bulman DE, Bultman SJ, Bultynck G, Burbulla LF, Bursch W, Butchar JP, Buzgariu W, Bydlowski SP, Cadwell K, Cahova M, Cai D, Cai J, Cai Q, Calabretta B, Calvo-Garrido J, Camougrand N, Campanella M, Campos-Salinas J, Candi E, Cao L, Caplan AB, Carding SR, Cardoso SM, Carew JS, Carlin CR, Carmignac V, Carneiro LA, Carra S, Caruso RA, Casari G, Casas C, Castino R, Cebollero E, Cecconi F, Celli J, Chaachouay H, Chae HJ, Chai CY, Chan DC, Chan EY, Chang RC, Che CM, Chen CC, Chen GC, Chen GQ, Chen M, Chen Q, Chen SS, Chen W, Chen X, Chen YG, Chen Y, Chen YJ, Chen Z, Cheng A, Cheng CH, Cheng Y, Cheong H, Cheong JH, Cherry S, Chess-Williams R, Cheung ZH, Chevet E, Chiang HL, Chiarelli R, Chiba T, Chin LS, Chiou SH, Chisari FV, Cho CH, Cho DH, Choi AM, Choi D, Choi KS, Choi ME, Chouaib S, Choubey D, Choubey V, Chu CT, Chuang TH, Chueh SH, Chun T, Chwae YJ, Chye ML, Ciarcia R, Ciriolo MR, Clague MJ, Clark RS, Clarke PG, Clarke R, Codogno P, Coller HA, Colombo MI, Comincini S, Condello M, Condorelli F, Cookson MR, Coombs GH, Coppens I, Corbalan R, Cossart P, Costelli P, Costes S, Coto-Montes A, Couve E, Coxon FP, Cregg JM, Crespo JL, Cronje MJ, Cuervo AM, Cullen JJ, Czaja MJ, D’Amelio M, Darfeuille-Michaud A, Davids LM, Davies FE, De Felici M, de Groot JF, de Haan CA, De Martino L, De Milito A, De Tata V, Debnath J, Degterev A, Dehay B, Delbridge LM, Demarchi F, Deng YZ, Dengjel J, Dent P, Denton D, Deretic V, Desai SD, Devenish RJ, Di Gioacchino M, Di Paolo G, Di Pietro C, Diaz-Araya G, Diaz-Laviada I, Diaz-Meco MT, Diaz-Nido J, Dikic I, Dinesh-Kumar SP, Ding WX, Distelhorst CW, Diwan A, Djavaheri-Mergny M, Dokudovskaya S, Dong Z, Dorsey FC, Dosenko V, Dowling JJ, Doxsey S, Dreux M, Drew ME, Duan Q, Duchosal MA, Duff K, Dugail I, Durbeej M, Duszenko M, Edelstein CL, Edinger AL, Egea G, Eichinger L, Eissa NT, Ekmekcioglu S, El-Deiry WS, Elazar Z, Elgendy M, Ellerby LM, Eng KE, Engelbrecht AM, Engelender S, Erenpreisa J, Escalante R, Esclatine A, Eskelinen EL, Espert L, Espina V, Fan H, Fan J, Fan QW, Fan Z, Fang S, Fang Y, Fanto M, Fanzani A, Farkas T, Farre JC, Faure M, Fechheimer M, Feng CG, Feng J, Feng Q, Feng Y, Fesus L, Feuer R, Figueiredo-Pereira ME, Fimia GM, Fingar DC, Finkbeiner S, Finkel T, Finley KD, Fiorito F, Fisher EA, Fisher PB, Flajolet M, Florez-McClure ML, Florio S, Fon EA, Fornai F, Fortunato F, Fotedar R, Fowler DH, Fox HS, Franco R, Frankel LB, Fransen M, Fuentes JM, Fueyo J, Fujii J, Fujisaki K, Fujita E, Fukuda M, Furukawa RH, Gaestel M, Gailly P, Gajewska M, Galliot B, Galy V, Ganesh S, Ganetzky B, Ganley IG, Gao FB, Gao GF, Gao J, Garcia L, Garcia-Manero G, Garcia-Marcos M, Garmyn M, Gartel AL, Gatti E, Gautel M, Gawriluk TR, Gegg ME, Geng J, Germain M, Gestwicki JE, Gewirtz DA, Ghavami S, Ghosh P, Giammarioli AM, Giatromanolaki AN, Gibson SB, Gilkerson RW, Ginger ML, Ginsberg HN, Golab J, Goligorsky MS, Golstein P, Gomez-Manzano C, Goncu E, Gongora C, Gonzalez CD, Gonzalez R, Gonzalez-Estevez C, Gonzalez-Polo RA, Gonzalez-Rey E, Gorbunov NV, Gorski S, Goruppi S, Gottlieb RA, Gozuacik D, Granato GE, Grant GD, Green KN, Gregorc A, Gros F, Grose C, Grunt TW, Gual P, Guan JL, Guan KL, Guichard SM, Gukovskaya AS, Gukovsky I, Gunst J, Gustafsson AB, Halayko AJ, Hale AN, Halonen SK, Hamasaki M, Han F, Han T, Hancock MK, Hansen M, Harada H, Harada M, Hardt SE, Harper JW, Harris AL, Harris J, Harris SD, Hashimoto M, Haspel JA, Hayashi S, Hazelhurst LA, He C, He YW, Hebert MJ, Heidenreich KA, Helfrich MH, Helgason GV, Henske EP, Herman B, Herman PK, Hetz C, Hilfiker S, Hill JA, Hocking LJ, Hofman P, Hofmann TG, Hohfeld J, Holyoake TL, Hong MH, Hood DA, Hotamisligil GS, Houwerzijl EJ, Hoyer-Hansen M, Hu B, Hu CA, Hu HM, Hua Y, Huang C, Huang J, Huang S, Huang WP, Huber TB, Huh WK, Hung TH, Hupp TR, Hur GM, Hurley JB, Hussain SN, Hussey PJ, Hwang JJ, Hwang S, Ichihara A, Ilkhanizadeh S, Inoki K, Into T, Iovane V, Iovanna JL, Ip NY, Isaka Y, Ishida H, Isidoro C, Isobe K, Iwasaki A, Izquierdo M, Izumi Y, Jaakkola PM, Jaattela M, Jackson GR, Jackson WT, Janji B, Jendrach M, Jeon JH, Jeung EB, Jiang H, Jiang JX, Jiang M, Jiang Q, Jiang X, Jimenez A, Jin M, Jin S, Joe CO, Johansen T, Johnson DE, Johnson GV, Jones NL, Joseph B, Joseph SK, Joubert AM, Juhasz G, Juillerat-Jeanneret L, Jung CH, Jung YK, Kaarniranta K, Kaasik A, Kabuta T, Kadowaki M, Kagedal K, Kamada Y, Kaminskyy VO, Kampinga HH, Kanamori H, Kang C, Kang KB, Kang KI, Kang R, Kang YA, Kanki T, Kanneganti TD, Kanno H, Kanthasamy AG, Kanthasamy A, Karantza V, Kaushal GP, Kaushik S, Kawazoe Y, Ke PY, Kehrl JH, Kelekar A, Kerkhoff C, Kessel DH, Khalil H, Kiel JA, Kiger AA, Kihara A, Kim DR, Kim DH, Kim EK, Kim HR, Kim JS, Kim JH, Kim JC, Kim JK, Kim PK, Kim SW, Kim YS, Kim Y, Kimchi A, Kimmelman AC, King JS, Kinsella TJ, Kirkin V, Kirshenbaum LA, Kitamoto K, Kitazato K, Klein L, Klimecki WT, Klucken J, Knecht E, Ko BC, Koch JC, Koga H, Koh JY, Koh YH, Koike M, Komatsu M, Kominami E, Kong HJ, Kong WJ, Korolchuk VI, Kotake Y, Koukourakis MI, Kouri Flores JB, Kovacs AL, Kraft C, Krainc D, Kramer H, Kretz-Remy C, Krichevsky AM, Kroemer G, Kruger R, Krut O, Ktistakis NT, Kuan CY, Kucharczyk R, Kumar A, Kumar R, Kumar S, Kundu M, Kung HJ, Kurz T, Kwon HJ, La Spada AR, Lafont F, Lamark T, Landry J, Lane JD, Lapaquette P, Laporte JF, Laszlo L, Lavandero S, Lavoie JN, Layfield R, Lazo PA, Le W, Le Cam L, Ledbetter DJ, Lee AJ, Lee BW, Lee GM, Lee J, Lee JH, Lee M, Lee MS, Lee SH, Leeuwenburgh C, Legembre P, Legouis R, Lehmann M, Lei HY, Lei QY, Leib DA, Leiro J, Lemasters JJ, Lemoine A, Lesniak MS, Lev D, Levenson VV, Levine B, Levy E, Li F, Li JL, Li L, Li S, Li W, Li XJ, Li YB, Li YP, Liang C, Liang Q, Liao YF, Liberski PP, Lieberman A, Lim HJ, Lim KL, Lim K, Lin CF, Lin FC, Lin J, Lin JD, Lin K, Lin WW, Lin WC, Lin YL, Linden R, Lingor P, Lippincott-Schwartz J, Lisanti MP, Liton PB, Liu B, Liu CF, Liu K, Liu L, Liu QA, Liu W, Liu YC, Liu Y, Lockshin RA, Lok CN, Lonial S, Loos B, Lopez-Berestein G, Lopez-Otin C, Lossi L, Lotze MT, Low P, Lu B, Lu Z, Luciano F, Lukacs NW, Lund AH, Lynch-Day MA, Ma Y, Macian F, MacKeigan JP, Macleod KF, Madeo F, Maiuri L, Maiuri MC, Malagoli D, Malicdan MC, Malorni W, Man N, Mandelkow EM, Manon S, Manov I, Mao K, Mao X, Mao Z, Marambaud P, Marazziti D, Marcel YL, Marchbank K, Marchetti P, Marciniak SJ, Marcondes M, Mardi M, Marfe G, Marino G, Markaki M, Marten MR, Martin SJ, Martinand-Mari C, Martinet W, Martinez-Vicente M, Masini M, Matarrese P, Matsuo S, Matteoni R, Mayer A, Mazure NM, McConkey DJ, McConnell MJ, McDermott C, McDonald C, McInerney GM, McKenna SL, McLaughlin B, McLean PJ, McMaster CR, McQuibban GA, Meijer AJ, Meisler MH, Melendez A, Melia TJ, Melino G, Mena MA, Menendez JA, Menna-Barreto RF, Menon MB, Menzies FM, Mercer CA, Merighi A, Merry DE, Meschini S, Meyer CG, Meyer TF, Miao CY, Miao JY, Michels PA, Michiels C, Mijaljica D, Milojkovic A, Minucci S, Miracco C, Miranti CK, Mitroulis I, Miyazawa K, Mizushima N, Mograbi B, Mohseni S, Molero X, Mollereau B, Mollinedo F, Momoi T, Monastyrska I, Monick MM, Monteiro MJ, Moore MN, Mora R, Moreau K, Moreira PI, Moriyasu Y, Moscat J, Mostowy S, Mottram JC, Motyl T, Moussa CE, Muller S, Munger K, Munz C, Murphy LO, Murphy ME, Musaro A, Mysorekar I, Nagata E, Nagata K, Nahimana A, Nair U, Nakagawa T, Nakahira K, Nakano H, Nakatogawa H, Nanjundan M, Naqvi NI, Narendra DP, Narita M, Navarro M, Nawrocki ST, Nazarko TY, Nemchenko A, Netea MG, Neufeld TP, Ney PA, Nezis IP, Nguyen HP, Nie D, Nishino I, Nislow C, Nixon RA, Noda T, Noegel AA, Nogalska A, Noguchi S, Notterpek L, Novak I, Nozaki T, Nukina N, Nurnberger T, Nyfeler B, Obara K, Oberley TD, Oddo S, Ogawa M, Ohashi T, Okamoto K, Oleinick NL, Oliver FJ, Olsen LJ, Olsson S, Opota O, Osborne TF, Ostrander GK, Otsu K, Ou JH, Ouimet M, Overholtzer M, Ozpolat B, Paganetti P, Pagnini U, Pallet N, Palmer GE, Palumbo C, Pan T, Panaretakis T, Pandey UB, Papackova Z, Papassideri I, Paris I, Park J, Park OK, Parys JB, Parzych KR, Patschan S, Patterson C, Pattingre S, Pawelek JM, Peng J, Perlmutter DH, Perrotta I, Perry G, Pervaiz S, Peter M, Peters GJ, Petersen M, Petrovski G, Phang JM, Piacentini M, Pierre P, Pierrefite-Carle V, Pierron G, Pinkas-Kramarski R, Piras A, Piri N, Platanias LC, Poggeler S, Poirot M, Poletti A, Pous C, Pozuelo-Rubio M, Praetorius-Ibba M, Prasad A, Prescott M, Priault M, Produit-Zengaffinen N, Progulske-Fox A, Proikas-Cezanne T, Przedborski S, Przyklenk K, Puertollano R, Puyal J, Qian SB, Qin L, Qin ZH, Quaggin SE, Raben N, Rabinowich H, Rabkin SW, Rahman I, Rami A, Ramm G, Randall G, Randow F, Rao VA, Rathmell JC, Ravikumar B, Ray SK, Reed BH, Reed JC, Reggiori F, Regnier-Vigouroux A, Reichert AS, Reiners JJ Jr, Reiter RJ, Ren J, Revuelta JL, Rhodes CJ, Ritis K, Rizzo E, Robbins J, Roberge M, Roca H, Roccheri MC, Rocchi S, Rodemann HP, Rodriguez de Cordoba S, Rohrer B, Roninson IB, Rosen K, Rost-Roszkowska MM, Rouis M, Rouschop KM, Rovetta F, Rubin BP, Rubinsztein DC, Ruckdeschel K, Rucker EB 3rd, Rudich A, Rudolf E, Ruiz-Opazo N, Russo R, Rusten TE, Ryan KM, Ryter SW, Sabatini DM, Sadoshima J, Saha T, Saitoh T, Sakagami H, Sakai Y, Salekdeh GH, Salomoni P, Salvaterra PM, Salvesen G, Salvioli R, Sanchez AM, Sanchez-Alcazar JA, Sanchez-Prieto R, Sandri M, Sankar U, Sansanwal P, Santambrogio L, Saran S, Sarkar S, Sarwal M, Sasakawa C, Sasnauskiene A, Sass M, Sato K, Sato M, Schapira AH, Scharl M, Schatzl HM, Scheper W, Schiaffino S, Schneider C, Schneider ME, Schneider-Stock R, Schoenlein PV, Schorderet DF, Schuller C, Schwartz GK, Scorrano L, Sealy L, Seglen PO, Segura-Aguilar J, Seiliez I, Seleverstov O, Sell C, Seo JB, Separovic D, Setaluri V, Setoguchi T, Settembre C, Shacka JJ, Shanmugam M, Shapiro IM, Shaulian E, Shaw RJ, Shelhamer JH, Shen HM, Shen WC, Sheng ZH, Shi Y, Shibuya K, Shidoji Y, Shieh JJ, Shih CM, Shimada Y, Shimizu S, Shintani T, Shirihai OS, Shore GC, Sibirny AA, Sidhu SB, Sikorska B, Silva-Zacarin EC, Simmons A, Simon AK, Simon HU, Simone C, Simonsen A, Sinclair DA, Singh R, Sinha D, Sinicrope FA, Sirko A, Siu PM, Sivridis E, Skop V, Skulachev VP, Slack RS, Smaili SS, Smith DR, Soengas MS, Soldati T, Song X, Sood AK, Soong TW, Sotgia F, Spector SA, Spies CD, Springer W, Srinivasula SM, Stefanis L, Steffan JS, Stendel R, Stenmark H, Stephanou A, Stern ST, Sternberg C, Stork B, Stralfors P, Subauste CS, Sui X, Sulzer D, Sun J, Sun SY, Sun ZJ, Sung JJ, Suzuki K, Suzuki T, Swanson MS, Swanton C, Sweeney ST, Sy LK, Szabadkai G, Tabas I, Taegtmeyer H, Tafani M, Takacs-Vellai K, Takano Y, Takegawa K, Takemura G, Takeshita F, Talbot NJ, Tan KS, Tanaka K, Tang D, Tanida I, Tannous BA, Tavernarakis N, Taylor GS, Taylor GA, Taylor JP, Terada LS, Terman A, Tettamanti G, Thevissen K, Thompson CB, Thorburn A, Thumm M, Tian F, Tian Y, Tocchini-Valentini G, Tolkovsky AM, Tomino Y, Tonges L, Tooze SA, Tournier C, Tower J, Towns R, Trajkovic V, Travassos LH, Tsai TF, Tschan MP, Tsubata T, Tsung A, Turk B, Turner LS, Tyagi SC, Uchiyama Y, Ueno T, Umekawa M, Umemiya-Shirafuji R, Unni VK, Vaccaro MI, Valente EM, Van den Berghe G, van der Klei IJ, van Doorn W, van Dyk LF, van Egmond M, van Grunsven LA, Vandenabeele P, Vandenberghe WP, Vanhorebeek I, Vaquero EC, Velasco G, Vellai T, Vicencio JM, Vierstra RD, Vila M, Vindis C, Viola G, Viscomi MT, Voitsekhovskaja OV, von Haefen C, Votruba M, Wada K, Wade-Martins R, Walker CL, Walsh CM, Walter J, Wan XB, Wang A, Wang C, Wang D, Wang F, Wang G, Wang H, Wang HG, Wang HD, Wang J, Wang K, Wang M, Wang RC, Wang X, Wang YJ, Wang Y, Wang Z, Wang ZC, Wansink DG, Ward DM, Watada H, Waters SL, Webster P, Wei L, Weihl CC, Weiss WA, Welford SM, Wen LP, Whitehouse CA, Whitton JL, Whitworth AJ, Wileman T, Wiley JW, Wilkinson S, Willbold D, Williams RL, Williamson PR, Wouters BG, Wu C, Wu DC, Wu WK, Wyttenbach A, Xavier RJ, Xi Z, Xia P, Xiao G, Xie Z, Xu DZ, Xu J, Xu L, Xu X, Yamamoto A, Yamashina S, Yamashita M, Yan X, Yanagida M, Yang DS, Yang E, Yang JM, Yang SY, Yang W, Yang WY, Yang Z, Yao MC, Yao TP, Yeganeh B, Yen WL, Yin JJ, Yin XM, Yoo OJ, Yoon G, Yoon SY, Yorimitsu T, Yoshikawa Y, Yoshimori T, Yoshimoto K, You HJ, Youle RJ, Younes A, Yu L, Yu SW, Yu WH, Yuan ZM, Yue Z, Yun CH, Yuzaki M, Zabirnyk O, Silva-Zacarin E, Zacks D, Zacksenhaus E, Zaffaroni N, Zakeri Z, Zeh HJ 3rd, Zeitlin SO, Zhang H, Zhang HL, Zhang J, Zhang JP, Zhang L, Zhang MY, Zhang XD, Zhao M, Zhao YF, Zhao Y, Zhao ZJ, Zheng X, Zhivotovsky B, Zhong Q, Zhou CZ, Zhu C, Zhu WG, Zhu XF, Zhu X, Zhu Y, Zoladek T, Zong WX, Zorzano A, Zschocke J, Zuckerbraun B (2012) Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8(4):445–544Google Scholar
  20. 20.
    Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA (2004) Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci U S A 101(6):1566–1571.  https://doi.org/10.1073/pnas.0308319100CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Hartman J, Lindberg K, Inzunza J, Wan J, Strom A, Gustafsson J (2006) Estrogen receptor beta represses breast tumor growth and angiogenesis in vivo. J Clin Oncol 24(18):565s–565sGoogle Scholar
  22. 22.
    Vivar OI, Zhao X, Saunier EF, Griffin C, Mayba OS, Tagliaferri M, Cohen I, Speed TP, Leitman DC (2010) Estrogen receptor beta binds to and regulates three distinct classes of target genes. J Biol Chem 285(29):22059–22066.  https://doi.org/10.1074/jbc.M110.114116CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Thomas C, Rajapaksa G, Nikolos F, Hao R, Katchy A, McCollum CW, Bondesson M, Quinlan P, Thompson A, Krishnamurthy S, Esteva FJ, Gustafsson JA (2012) ERbeta1 represses basal-like breast cancer epithelial to mesenchymal transition by destabilizing EGFR. Breast Cancer Res 14(6):R148.  https://doi.org/10.1186/bcr3358CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Gomez BP, Riggins RB, Shajahan AN, Klimach U, Wang A, Crawford AC, Zhu Y, Zwart A, Wang M, Clarke R (2007) Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines. FASEB J 21(14):4013–4027.  https://doi.org/10.1096/fj.06-7990comCrossRefPubMedGoogle Scholar
  25. 25.
    Picard N, Charbonneau C, Sanchez M, Licznar A, Busson M, Lazennec G, Tremblay A (2008) Phosphorylation of activation function-1 regulates proteasome-dependent nuclear mobility and E6-associated protein ubiquitin ligase recruitment to the estrogen receptor beta. Mol Endocrinol 22(2):317–330.  https://doi.org/10.1210/me.2007-0281CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Thomas C, Gustafsson JA (2012) Targeting PES1 for restoring the ERalpha/ERbeta ratio in breast cancer. J Clin Invest 122(8):2771–2773.  https://doi.org/10.1172/JCI65133CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Cheng L, Li J, Han Y, Lin J, Niu C, Zhou Z, Yuan B, Huang K, Jiang K, Zhang H, Ding L, Xu X, Ye Q (2012) PES1 promotes breast cancer by differentially regulating ERalpha and ERbeta. J Clin Invest 122(8):2857–2870.  https://doi.org/10.1172/JCI62676CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Tremblay A, Tremblay GB, Labrie F, Giguere V (1999) Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. Mol Cell 3(4):513–519CrossRefGoogle Scholar
  29. 29.
    Yuan B, Cheng L, Chiang HC, Xu X, Han Y, Su H, Wang L, Zhang B, Lin J, Li X, Xie X, Wang T, Tekmal RR, Curiel TJ, Yuan ZM, Elledge R, Hu Y, Ye Q, Li R (2014) A phosphotyrosine switch determines the antitumor activity of ERbeta. J Clin Invest 124(8):3378–3390.  https://doi.org/10.1172/JCI74085CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Yuan B, Cheng L, Gupta K, Chiang HC, Gupta HB, Sareddy GR, Wang D, Lathrop K, Elledge R, Wang P, McHardy S, Vadlamudi R, Curiel TJ, Hu Y, Ye Q, Li R (2016) Tyrosine phosphorylation regulates ERbeta ubiquitination, protein turnover, and inhibition of breast cancer. Oncotarget 7(27):42585–42597.  https://doi.org/10.18632/oncotarget.10018CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Roger P, Sahla ME, Makela S, Gustafsson JA, Baldet P, Rochefort H (2001) Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 61(6):2537–2541PubMedGoogle Scholar
  32. 32.
    Skliris GP, Munot K, Bell SM, Carder PJ, Lane S, Horgan K, Lansdown MR, Parkes AT, Hanby AM, Markham AF, Speirs V (2003) Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol 201(2):213–220.  https://doi.org/10.1002/path.1436CrossRefPubMedGoogle Scholar
  33. 33.
    Huang B, Omoto Y, Iwase H, Yamashita H, Toyama T, Coombes RC, Filipovic A, Warner M, Gustafsson JA (2014) Differential expression of estrogen receptor alpha, beta1, and beta2 in lobular and ductal breast cancer. Proc Natl Acad Sci U S A 111(5):1933–1938.  https://doi.org/10.1073/pnas.1323719111CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Hieken TJ, Carter JM, Hawse JR, Hoskin TL, Bois M, Frost M, Hartmann LC, Radisky DC, Visscher DW, Degnim AC (2015) ERbeta expression and breast cancer risk prediction for women with atypias. Cancer Prev Res (Phila) 8(11):1084–1092.  https://doi.org/10.1158/1940-6207.CAPR-15-0198CrossRefGoogle Scholar
  35. 35.
    Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P (2004) Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 11(3):537–551CrossRefGoogle Scholar
  36. 36.
    Bado I, Nikolos F, Rajapaksa G, Wu W, Castaneda J, Krishnamurthy S, Webb P, Gustafsson JA, Thomas C (2017) Somatic loss of estrogen receptor beta and p53 synergize to induce breast tumorigenesis. Breast Cancer Res 19(1):79.  https://doi.org/10.1186/s13058-017-0872-zCrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Swedenborg E, Power KA, Cai W, Pongratz I, Ruegg J (2009) Regulation of estrogen receptor beta activity and implications in health and disease. Cell Mol Life Sci 66(24):3873–3894.  https://doi.org/10.1007/s00018-009-0118-zCrossRefPubMedGoogle Scholar
  38. 38.
    Rody A, Holtrich U, Solbach C, Kourtis K, von Minckwitz G, Engels K, Kissler S, Gatje R, Karn T, Kaufmann M (2005) Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocr Relat Cancer 12(4):903–916.  https://doi.org/10.1677/erc.1.01088CrossRefPubMedGoogle Scholar
  39. 39.
    Zhao C, Lam EW, Sunters A, Enmark E, De Bella MT, Coombes RC, Gustafsson JA, Dahlman-Wright K (2003) Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene 22(48):7600–7606.  https://doi.org/10.1038/sj.onc.1207100CrossRefPubMedGoogle Scholar
  40. 40.
    Al-Nakhle H, Burns PA, Cummings M, Hanby AM, Hughes TA, Satheesha S, Shaaban AM, Smith L, Speirs V (2010) Estrogen receptor {beta}1 expression is regulated by miR-92 in breast cancer. Cancer Res 70(11):4778–4784.  https://doi.org/10.1158/0008-5472.CAN-09-4104CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Tateishi Y, Kawabe Y, Chiba T, Murata S, Ichikawa K, Murayama A, Tanaka K, Baba T, Kato S, Yanagisawa J (2004) Ligand-dependent switching of ubiquitin-proteasome pathways for estrogen receptor. EMBO J 23(24):4813–4823.  https://doi.org/10.1038/sj.emboj.7600472CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Pratt WB, Toft DO (1997) Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 18(3):306–360.  https://doi.org/10.1210/edrv.18.3.0303CrossRefPubMedGoogle Scholar
  43. 43.
    Bagatell R, Khan O, Paine-Murrieta G, Taylor CW, Akinaga S, Whitesell L (2001) Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer. Clin Cancer Res 7(7):2076–2084PubMedGoogle Scholar
  44. 44.
    Tateishi Y, Sonoo R, Sekiya Y, Sunahara N, Kawano M, Wayama M, Hirota R, Kawabe Y, Murayama A, Kato S, Kimura K, Yanagisawa J (2006) Turning off estrogen receptor beta-mediated transcription requires estrogen-dependent receptor proteolysis. Mol Cell Biol 26(21):7966–7976.  https://doi.org/10.1128/MCB.00713-06CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Fan M, Park A, Nephew KP (2005) CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptor-alpha. Mol Endocrinol 19(12):2901–2914.  https://doi.org/10.1210/me.2005-0111CrossRefPubMedGoogle Scholar
  46. 46.
    Alonso L, Gallego E, Gonzalez FJ, Sanchez-Munoz A, Torres E, Pajares BI, Leeflang S, Baha C (2009) Gonadotropin and steroid receptors as prognostic factors in advanced ovarian cancer: a retrospective study. Clin Transl Oncol 11(11):748–752CrossRefGoogle Scholar
  47. 47.
    Ohshiro K, Kumar R (2015) MTA1 regulation of ERbeta pathway in salivary gland carcinoma cells. Biochem Biophys Res Commun 464(4):1016–1021.  https://doi.org/10.1016/j.bbrc.2015.07.043CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Zhao Z, Wang L, James T, Jung Y, Kim I, Tan R, Hoffmann FM, Xu W (2015) Reciprocal regulation of ERalpha and ERbeta stability and activity by diptoindonesin G. Chem Biol 22(12):1608–1621.  https://doi.org/10.1016/j.chembiol.2015.10.011CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Sternlicht MD (2006) Key stages in mammary gland development: the cues that regulate ductal branching morphogenesis. Breast Cancer Res 8(1):201.  https://doi.org/10.1186/bcr1368CrossRefPubMedGoogle Scholar
  50. 50.
    Korach KS, Couse JF, Curtis SW, Washburn TF, Lindzey J, Kimbro KS, Eddy EM, Migliaccio S, Snedeker SM, Lubahn DB, Schomberg DW, Smith EP (1996) Estrogen receptor gene disruption: molecular characterization and experimental and clinical phenotypes. Recent Prog Horm Res 51:159–186 discussion 186–158PubMedGoogle Scholar
  51. 51.
    Mallepell S, Krust A, Chambon P, Brisken C (2006) Paracrine signaling through the epithelial estrogen receptor alpha is required for proliferation and morphogenesis in the mammary gland. Proc Natl Acad Sci U S A 103(7):2196–2201.  https://doi.org/10.1073/pnas.0510974103CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Ciarloni L, Mallepell S, Brisken C (2007) Amphiregulin is an essential mediator of estrogen receptor alpha function in mammary gland development. Proc Natl Acad Sci U S A 104(13):5455–5460.  https://doi.org/10.1073/pnas.0611647104CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Forster C, Makela S, Warri A, Kietz S, Becker D, Hultenby K, Warner M, Gustafsson JA (2002) Involvement of estrogen receptor beta in terminal differentiation of mammary gland epithelium. Proc Natl Acad Sci U S A 99(24):15578–15583.  https://doi.org/10.1073/pnas.192561299CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Antal MC, Krust A, Chambon P, Mark M (2008) Sterility and absence of histopathological defects in nonreproductive organs of a mouse ERbeta-null mutant. Proc Natl Acad Sci U S A 105(7):2433–2438.  https://doi.org/10.1073/pnas.0712029105CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Helguero LA, Faulds MH, Gustafsson JA, Haldosen LA (2005) Estrogen receptors alfa (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene 24(44):6605–6616.  https://doi.org/10.1038/sj.onc.1208807CrossRefPubMedGoogle Scholar
  56. 56.
    Treeck O, Pfeiler G, Mitter D, Lattrich C, Piendl G, Ortmann O (2007) Estrogen receptor {beta}1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells. J Endocrinol 193(3):421–433.  https://doi.org/10.1677/JOE-07-0087CrossRefPubMedGoogle Scholar
  57. 57.
    Treeck O, Lattrich C, Springwald A, Ortmann O (2010) Estrogen receptor beta exerts growth-inhibitory effects on human mammary epithelial cells. Breast Cancer Res Treat 120(3):557–565.  https://doi.org/10.1007/s10549-009-0413-2CrossRefPubMedGoogle Scholar
  58. 58.
    Cotrim CZ, Fabris V, Doria ML, Lindberg K, Gustafsson JA, Amado F, Lanari C, Helguero LA (2013) Estrogen receptor beta growth-inhibitory effects are repressed through activation of MAPK and PI3K signalling in mammary epithelial and breast cancer cells. Oncogene 32(19):2390–2402.  https://doi.org/10.1038/onc.2012.261CrossRefPubMedGoogle Scholar
  59. 59.
    Sotoca AM, van den Berg H, Vervoort J, van der Saag P, Strom A, Gustafsson JA, Rietjens I, Murk AJ (2008) Influence of cellular ERalpha/ERbeta ratio on the ERalpha-agonist induced proliferation of human T47D breast cancer cells. Toxicol Sci 105(2):303–311.  https://doi.org/10.1093/toxsci/kfn141CrossRefPubMedGoogle Scholar
  60. 60.
    Wiesen JF, Young P, Werb Z, Cunha GR (1999) Signaling through the stromal epidermal growth factor receptor is necessary for mammary ductal development. Development 126(2):335–344PubMedGoogle Scholar
  61. 61.
    Samanta S, Sharma VM, Khan A, Mercurio AM (2012) Regulation of IMP3 by EGFR signaling and repression by ERbeta: implications for triple-negative breast cancer. Oncogene 31:4689.  https://doi.org/10.1038/onc.2011.620CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Song W, Tang L, Xu Y, Sun Q, Yang F, Guan X (2017) ERbeta1 inhibits metastasis of androgen receptor-positive triple-negative breast cancer by suppressing ZEB1. J Exp Clin Cancer Res 36(1):75.  https://doi.org/10.1186/s13046-017-0545-xCrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Schuler-Toprak S, Haring J, Inwald EC, Moehle C, Ortmann O, Treeck O (2016) Agonists and knockdown of estrogen receptor beta differentially affect invasion of triple-negative breast cancer cells in vitro. BMC Cancer 16(1):951.  https://doi.org/10.1186/s12885-016-2973-yCrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Hinsche O, Girgert R, Emons G, Grundker C (2015) Estrogen receptor beta selective agonists reduce invasiveness of triple-negative breast cancer cells. Int J Oncol 46(2):878–884.  https://doi.org/10.3892/ijo.2014.2778CrossRefPubMedGoogle Scholar
  65. 65.
    Vladusic EA, Hornby AE, Guerra-Vladusic FK, Lupu R (1998) Expression of estrogen receptor beta messenger RNA variant in breast cancer. Cancer Res 58(2):210–214PubMedGoogle Scholar
  66. 66.
    Poola I, Fuqua SA, De Witty RL, Abraham J, Marshallack JJ, Liu A (2005) Estrogen receptor alpha-negative breast cancer tissues express significant levels of estrogen-independent transcription factors, ERbeta1 and ERbeta5: potential molecular targets for chemoprevention. Clin Cancer Res 11(20):7579–7585.  https://doi.org/10.1158/1078-0432.CCR-05-0728CrossRefPubMedGoogle Scholar
  67. 67.
    Omoto Y, Eguchi H, Yamamoto-Yamaguchi Y, Hayashi S (2003) Estrogen receptor (ER) beta1 and ERbetacx/beta2 inhibit ERalpha function differently in breast cancer cell line MCF7. Oncogene 22(32):5011–5020.  https://doi.org/10.1038/sj.onc.1206787CrossRefPubMedGoogle Scholar
  68. 68.
    Rajapaksa G, Nikolos F, Bado I, Clarke R, Gustafsson JA, Thomas C (2015) ERbeta decreases breast cancer cell survival by regulating the IRE1/XBP-1 pathway. Oncogene 34(31):4130–4141.  https://doi.org/10.1038/onc.2014.343CrossRefPubMedGoogle Scholar
  69. 69.
    Secreto FJ, Monroe DG, Dutta S, Ingle JN, Spelsberg TC (2007) Estrogen receptor alpha/beta isoforms, but not betacx, modulate unique patterns of gene expression and cell proliferation in Hs578T cells. J Cell Biochem 101(5):1125–1147.  https://doi.org/10.1002/jcb.21205CrossRefPubMedGoogle Scholar
  70. 70.
    Bialesova L, Xu L, Gustafsson JA, Haldosen LA, Zhao C, Dahlman-Wright K (2017) Estrogen receptor beta2 induces proliferation and invasiveness of triple negative breast cancer cells: association with regulation of PHD3 and HIF-1alpha. Oncotarget 8(44):76622–76633.  https://doi.org/10.18632/oncotarget.20635CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Faria M, Karami S, Granados-Principal S, Dey P, Verma A, Choi DS, Elemento O, Bawa-Khalfe T, Chang JC, Strom AM, Gustafsson JA (2018) The ERbeta4 variant induces transformation of the normal breast mammary epithelial cell line MCF-10A; the ERbeta variants ERbeta2 and ERbeta5 increase aggressiveness of TNBC by regulation of hypoxic signaling. Oncotarget 9(15):12201–12211.  https://doi.org/10.18632/oncotarget.24134CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Shaaban AM, Green AR, Karthik S, Alizadeh Y, Hughes TA, Harkins L, Ellis IO, Robertson JF, Paish EC, Saunders PT, Groome NP, Speirs V (2008) Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res 14(16):5228–5235.  https://doi.org/10.1158/1078-0432.CCR-07-4528CrossRefPubMedGoogle Scholar
  73. 73.
    Palmieri C, Cheng GJ, Saji S, Zelada-Hedman M, Warri A, Weihua Z, Van Noorden S, Wahlstrom T, Coombes RC, Warner M, Gustafsson JA (2002) Estrogen receptor beta in breast cancer. Endocr Relat Cancer 9(1):1–13CrossRefGoogle Scholar
  74. 74.
    Haldosen LA, Zhao C, Dahlman-Wright K (2014) Estrogen receptor beta in breast cancer. Mol Cell Endocrinol 382(1):665–672.  https://doi.org/10.1016/j.mce.2013.08.005CrossRefPubMedGoogle Scholar
  75. 75.
    Hartman J, Lindberg K, Morani A, Inzunza J, Strom A, Gustafsson JA (2006) Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res 66(23):11207–11213.  https://doi.org/10.1158/0008-5472.CAN-06-0017CrossRefPubMedGoogle Scholar
  76. 76.
    Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC (2004) Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 64(1):423–428CrossRefGoogle Scholar
  77. 77.
    Shanle EK, Zhao Z, Hawse J, Wisinski K, Keles S, Yuan M, Xu W (2013) Research resource: global identification of estrogen receptor beta target genes in triple negative breast cancer cells. Mol Endocrinol 27(10):1762–1775.  https://doi.org/10.1210/me.2013-1164CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F (2001) ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 142(9):4120–4130.  https://doi.org/10.1210/endo.142.9.8395CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Bivona TG, Hieronymus H, Parker J, Chang K, Taron M, Rosell R, Moonsamy P, Dahlman K, Miller VA, Costa C, Hannon G, Sawyers CL (2011) FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR. Nature 471(7339):523–526.  https://doi.org/10.1038/nature09870CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Lu W, Katzenellenbogen BS (2017) Estrogen receptor-beta modulation of the ERalpha-p53 loop regulating gene expression, proliferation, and apoptosis in breast cancer. Horm Cancer 8(4):230–242.  https://doi.org/10.1007/s12672-017-0298-1CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Reese JM, Bruinsma ES, Monroe DG, Negron V, Suman VJ, Ingle JN, Goetz MP, Hawse JR (2017) ERbeta inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer. Oncotarget 8(57):96506–96521.  https://doi.org/10.18632/oncotarget.21787CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Park C, Lee Y (2014) Overexpression of ERbeta is sufficient to inhibit hypoxia-inducible factor-1 transactivation. Biochem Biophys Res Commun 450(1):261–266.  https://doi.org/10.1016/j.bbrc.2014.05.107CrossRefPubMedGoogle Scholar
  83. 83.
    Murphy LC, Peng B, Lewis A, Davie JR, Leygue E, Kemp A, Ung K, Vendetti M, Shiu R (2005) Inducible upregulation of oestrogen receptor-beta1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells. J Mol Endocrinol 34(2):553–566.  https://doi.org/10.1677/jme.1.01688CrossRefPubMedGoogle Scholar
  84. 84.
    Bado I, Pham E, Soibam B, Nikolos F, Gustafsson J-Å, Thomas C (2018) ERβ alters the chemosensitivity of luminal breast cancer cells by regulating p53 function. Oncotarget 9(32):22509–22522. https://www.ncbi.nlm.nih.gov/pubmed/29854295
  85. 85.
    Lindberg K, Helguero LA, Omoto Y, Gustafsson JA, Haldosen LA (2011) Estrogen receptor beta represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity. Breast Cancer Res 13(2):R43.  https://doi.org/10.1186/bcr2865CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Thomas CG, Strom A, Lindberg K, Gustafsson JA (2011) Estrogen receptor beta decreases survival of p53-defective cancer cells after DNA damage by impairing G(2)/M checkpoint signaling. Breast Cancer Res Treat 127(2):417–427.  https://doi.org/10.1007/s10549-010-1011-zCrossRefPubMedGoogle Scholar
  87. 87.
    Rajapaksa G, Thomas C, Gustafsson JA (2016) Estrogen signaling and unfolded protein response in breast cancer. J Steroid Biochem Mol Biol 163:45.  https://doi.org/10.1016/j.jsbmb.2016.03.036CrossRefPubMedGoogle Scholar
  88. 88.
    Sanchez M, Picard N, Sauve K, Tremblay A (2013) Coordinate regulation of estrogen receptor beta degradation by Mdm2 and CREB-binding protein in response to growth signals. Oncogene 32(1):117–126.  https://doi.org/10.1038/onc.2012.19CrossRefPubMedGoogle Scholar
  89. 89.
    Jonsson P, Katchy A, Williams C (2014) Support of a bi-faceted role of estrogen receptor beta (ERbeta) in ERalpha-positive breast cancer cells. Endocr Relat Cancer 21(2):143–160.  https://doi.org/10.1530/ERC-13-0444CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Ma R, Karthik GM, Lovrot J, Haglund F, Rosin G, Katchy A, Zhang X, Viberg L, Frisell J, Williams C, Linder S, Fredriksson I, Hartman J (2017) Estrogen receptor beta as a therapeutic target in breast cancer stem cells. J Natl Cancer Inst 109(3):1–14.  https://doi.org/10.1093/jnci/djw236CrossRefPubMedGoogle Scholar
  91. 91.
    Moore JT, McKee DD, Slentz-Kesler K, Moore LB, Jones SA, Horne EL, Su JL, Kliewer SA, Lehmann JM, Willson TM (1998) Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun 247(1):75–78.  https://doi.org/10.1006/bbrc.1998.8738CrossRefGoogle Scholar
  92. 92.
    Green CA, Peter MB, Speirs V, Shaaban AM (2008) The potential role of ER beta isoforms in the clinical management of breast cancer. Histopathology 53(4):374–380.  https://doi.org/10.1111/j.1365-2559.2008.02968.xCrossRefPubMedGoogle Scholar
  93. 93.
    Zhao C, Matthews J, Tujague M, Wan J, Strom A, Toresson G, Lam EW, Cheng G, Gustafsson JA, Dahlman-Wright K (2007) Estrogen receptor beta2 negatively regulates the transactivation of estrogen receptor alpha in human breast cancer cells. Cancer Res 67(8):3955–3962.  https://doi.org/10.1158/0008-5472.CAN-06-3505CrossRefPubMedGoogle Scholar
  94. 94.
    Helguero LA, Lindberg K, Gardmo C, Schwend T, Gustafsson JA, Haldosen LA (2008) Different roles of estrogen receptors alpha and beta in the regulation of E-cadherin protein levels in a mouse mammary epithelial cell line. Cancer Res 68(21):8695–8704.  https://doi.org/10.1158/0008-5472.CAN-08-0788CrossRefPubMedGoogle Scholar
  95. 95.
    Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, Bowlby R, Shen H, Hayat S, Fieldhouse R, Lester SC, Tse GM, Factor RE, Collins LC, Allison KH, Chen YY, Jensen K, Johnson NB, Oesterreich S, Mills GB, Cherniack AD, Robertson G, Benz C, Sander C, Laird PW, Hoadley KA, King TA, Network TR, Perou CM (2015) Comprehensive molecular portraits of invasive lobular breast cancer. Cell 163(2):506–519.  https://doi.org/10.1016/j.cell.2015.09.033CrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    Bado I, Nikolos F, Rajapaksa G, Gustafsson JA, Thomas C (2016) ERbeta decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function. Oncotarget 7(12):13599–13611.  https://doi.org/10.18632/oncotarget.7300CrossRefPubMedPubMedCentralGoogle Scholar
  97. 97.
    Lindberg K, Strom A, Lock JG, Gustafsson JA, Haldosen LA, Helguero LA (2010) Expression of estrogen receptor beta increases integrin alpha 1 and integrin beta 1 levels and enhances adhesion of breast cancer cells. J Cell Physiol 222(1):156–167.  https://doi.org/10.1002/Jcp.21932CrossRefPubMedGoogle Scholar
  98. 98.
    Zhu X, Leav I, Leung YK, Wu M, Liu Q, Gao Y, McNeal JE, Ho SM (2004) Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am J Pathol 164(6):2003–2012CrossRefGoogle Scholar
  99. 99.
    Hankinson SE, Colditz GA, Willett WC (2004) Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Res 6(5):213–218.  https://doi.org/10.1186/bcr921CrossRefPubMedPubMedCentralGoogle Scholar
  100. 100.
    Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11(2):155–168PubMedGoogle Scholar
  101. 101.
    Speirs V, Green AR, Hughes TA, Ellis IO, Saunders PT, Shaaban AM (2008) Clinical importance of estrogen receptor beta isoforms in breast cancer. J Clin Oncol 26(35):5825.; author reply 5825–5826.  https://doi.org/10.1200/JCO.2008.19.5909CrossRefPubMedGoogle Scholar
  102. 102.
    Andersson S, Sundberg M, Pristovsek N, Ibrahim A, Jonsson P, Katona B, Clausson CM, Zieba A, Ramstrom M, Soderberg O, Williams C, Asplund A (2017) Insufficient antibody validation challenges oestrogen receptor beta research. Nat Commun 8:15840.  https://doi.org/10.1038/ncomms15840CrossRefPubMedPubMedCentralGoogle Scholar
  103. 103.
    Nikolos F, Thomas C, Rajapaksa G, Bado I, Gustafsson JA (2014) ERbeta regulates NSCLC phenotypes by controlling oncogenic RAS signaling. Mol Cancer Res 12:843.  https://doi.org/10.1158/1541-7786.MCR-13-0663CrossRefPubMedGoogle Scholar
  104. 104.
    Reese JM, Suman VJ, Subramaniam M, Wu X, Negron V, Gingery A, Pitel KS, Shah SS, Cunliffe HE, McCullough AE, Pockaj BA, Couch FJ, Olson JE, Reynolds C, Lingle WL, Spelsberg TC, Goetz MP, Ingle JN, Hawse JR (2014) ERbeta1: characterization, prognosis, and evaluation of treatment strategies in ERalpha-positive and -negative breast cancer. BMC Cancer 14:749.  https://doi.org/10.1186/1471-2407-14-749CrossRefPubMedPubMedCentralGoogle Scholar
  105. 105.
    Nakopoulou L, Lazaris AC, Panayotopoulou EG, Giannopoulou I, Givalos N, Markaki S, Keramopoulos A (2004) The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer. J Clin Pathol 57(5):523–528CrossRefGoogle Scholar
  106. 106.
    Marotti JD, Collins LC, Hu R, Tamimi RM (2010) Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses’ Health Study. Mod Pathol 23(2):197–204.  https://doi.org/10.1038/modpathol.2009.158CrossRefPubMedGoogle Scholar
  107. 107.
    Honma N, Horii R, Iwase T, Saji S, Younes M, Takubo K, Matsuura M, Ito Y, Akiyama F, Sakamoto G (2008) Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol 26(22):3727–3734.  https://doi.org/10.1200/JCO.2007.14.2968CrossRefPubMedGoogle Scholar
  108. 108.
    Yan M, Rayoo M, Takano EA, Fox SB (2011) Nuclear and cytoplasmic expressions of ERbeta1 and ERbeta2 are predictive of response to therapy and alters prognosis in familial breast cancers. Breast Cancer Res Treat 126(2):395–405.  https://doi.org/10.1007/s10549-010-0941-9CrossRefPubMedGoogle Scholar
  109. 109.
    Sugiura H, Toyama T, Hara Y, Zhang Z, Kobayashi S, Fujii Y, Iwase H, Yamashita H (2007) Expression of estrogen receptor beta wild-type and its variant ERbetacx/beta2 is correlated with better prognosis in breast cancer. Jpn J Clin Oncol 37(11):820–828.  https://doi.org/10.1093/jjco/hym114CrossRefPubMedGoogle Scholar
  110. 110.
    Honma N, Horii R, Iwase T, Saji S, Younes M, Ito Y, Akiyama F (2015) Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy. Breast Cancer 22(1):71–78.  https://doi.org/10.1007/s12282-013-0455-5CrossRefPubMedGoogle Scholar
  111. 111.
    O’Neill PA, Davies MP, Shaaban AM, Innes H, Torevell A, Sibson DR, Foster CS (2004) Wild-type oestrogen receptor beta (ERbeta1) mRNA and protein expression in tamoxifen-treated post-menopausal breast cancers. Br J Cancer 91(9):1694–1702.  https://doi.org/10.1038/sj.bjc.6602183CrossRefPubMedPubMedCentralGoogle Scholar
  112. 112.
    Elebro K, Borgquist S, Rosendahl AH, Markkula A, Simonsson M, Jirstrom K, Rose C, Ingvar C, Jernstrom H (2017) High estrogen receptor beta expression is prognostic among adjuvant chemotherapy-treated patients-results from a population-based breast cancer cohort. Clin Cancer Res 23(3):766–777.  https://doi.org/10.1158/1078-0432.CCR-16-1095CrossRefPubMedGoogle Scholar
  113. 113.
    Novelli F, Milella M, Melucci E, Di Benedetto A, Sperduti I, Perrone-Donnorso R, Perracchio L, Venturo I, Nistico C, Fabi A, Buglioni S, Natali PG, Mottolese M (2008) A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Breast Cancer Res 10(5):R74.  https://doi.org/10.1186/bcr2139CrossRefPubMedPubMedCentralGoogle Scholar
  114. 114.
    Wang J, Zhang C, Chen K, Tang H, Tang J, Song C, Xie X (2015) ERbeta1 inversely correlates with PTEN/PI3K/AKT pathway and predicts a favorable prognosis in triple-negative breast cancer. Breast Cancer Res Treat 152(2):255–269.  https://doi.org/10.1007/s10549-015-3467-3CrossRefPubMedGoogle Scholar
  115. 115.
    Tan W, Li Q, Chen K, Su F, Song E, Gong C (2016) Estrogen receptor beta as a prognostic factor in breast cancer patients: a systematic review and meta-analysis. Oncotarget 7(9):10373–10385.  https://doi.org/10.18632/oncotarget.7219CrossRefPubMedPubMedCentralGoogle Scholar
  116. 116.
    Liu J, Guo H, Mao K, Zhang K, Deng H, Liu Q (2016) Impact of estrogen receptor-beta expression on breast cancer prognosis: a meta-analysis. Breast Cancer Res Treat 156(1):149–162.  https://doi.org/10.1007/s10549-016-3721-3CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Christoforos Thomas
    • 1
  • Jan-Åke Gustafsson
    • 1
  1. 1.Department of Biology and Biochemistry, Center for Nuclear Receptors and Cell SignalingUniversity of HoustonHoustonUSA

Personalised recommendations